Ryan McDonald | Authors

Articles

Biomarkers May Help Predict Responses to Avelumab in Urothelial Carcinoma

September 11, 2022

Multiple blood-based biomarkers suggest potential responses to treatment with maintenance avelumab for patients with advanced or metastatic urothelial carcinoma from the phase 3 JAVELIN Bladder 100 trial, according to an exploratory analysis presented at the European Society for Medical Oncology Congress 2022.

KEYNOTE-799 Results Reveal Durable Responses in Previously Untreated Stage III NSCLC

June 09, 2022

In patients with previously untreated, locally advanced stage III non–small cell lung cancer, continued benefit from pembrolizumab with concurrent chemoradiation followed by additional pembrolizumab was observed after more than 2 years of follow-up.